Key result
Among 7.36 million elderly patients in South Korea, 47.8% had continuous polypharmacy for ≥90 days, with male sex, older age, and comorbidities associated with an increased probability.
Why the study?
Polypharmacy may cause adverse health outcomes in the elderly, prompting an examination of the prevalence, associated factors, and most frequently prescribed medications among older adults in South Korea.
What is the prevalence of and factors associated with continuous polypharmacy and hyper-polypharmacy among older adults in South Korea?
Cohort (n=7,358,953)
Yes
What is the prevalence of and factors associated with continuous polypharmacy and hyper-polypharmacy among older adults in South Korea?
A significant proportion of elderly patients in South Korea experience continuous polypharmacy and hyper-polypharmacy, strongly influenced by comorbidities and outpatient healthcare utilization.
High sustained polypharmacy prevalence supports monitoring in comorbid elderly; leaves open causal effects and intervention outcomes.
Polypharmacy may cause adverse health outcomes in the elderly. This study examined the prevalence of continuous polypharmacy and hyper-polypharmacy, factors associated with polypharmacy, and the most frequently prescribed medications among older adults in South Korea. This was a retrospective observational study using National Health Insurance claims data. In total, 7,358,953 Korean elderly patients aged 65 years and older were included. Continuous polypharmacy and hyper-polypharmacy were defined as the use of ≥5 and ≥10 medications, respectively, for both ≥90 days and ≥180 days within 1 year. A multivariate logistic regression analysis was conducted with adjustment for general characteristics (sex, age, insurance type), comorbidities (12 diseases, number of comorbidities, and Elixhauser Comorbidity Index [ECI] classification), and healthcare service utilization. Among 7.36 million elderly patients, 47.8% and 36.9% had polypharmacy for ≥90 and ≥180 days, and 11.9% and 7.1% of patients exhibited hyper-polypharmacy for ≥90 and ≥180 days, respectively. Male sex, older age, insurance, comorbidities (cardio-cerebrovascular disease, diabetes mellitus, depressive disorder, dementia, an ECI score of ≥3), and healthcare service utilization were associated with an increased probability of polypharmacy. The therapeutic class with the most prescriptions was drugs for acid-related disorders (ATC A02). The number of outpatient visit days more strongly influenced polypharmacy than hospitalizations and ED visits. This study provides health policymakers with important evidence about the critical need to reduce polypharmacy among older adults.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2022) conducted a cohort in Polypharmacy (n=7,358,953). Risk factors (male sex, older age, comorbidities, healthcare utilization) was evaluated on Prevalence of continuous polypharmacy and hyper-polypharmacy. Among 7.36 million elderly patients in South Korea, 47.8% had continuous polypharmacy for ≥90 days, with male sex, older age, and comorbidities associated with an increased probability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: